Top PLR Content Directory Australia: September 2016

Friday, September 23, 2016

Samsca

Samsca is a brand name of tolvaptan, approved by the FDA in the following formulation(s):

SAMSCA (tolvaptan - tablet; oral)

Manufacturer: OTSUKA AMERICA PHARM

Approval date: May 19, 2009

Strength(s): 15MG, 30MG ^[RLD]

Has a generic version of Samsca been approved?

No. There is currently no therapeutically equivalent version of Samsca available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Samsca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Benzoheterocyclic compounds
Patent 5,753,677
Issued: May 19, 1998
Inventor(s): Ogawa; Hidenori & Miyamoto; Hisashi & Kondo; Kazumi & Yamashita; Hiroshi & Nakaya; Kenji & Komatsu; Hajime & Tanaka; Michinori & Kora; Shinya & Tominaga; Michiaki & Yabuuchi; Yoichi
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Patent expiration dates:
- May 19, 2015
  ✓
  Patent use: METHOD OF TREATING HYPONATREMIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- May 19, 2014 - NEW CHEMICAL ENTITY

Has a generic version of Comtan been approved?

No. There is currently no therapeutically equivalent version of Comtan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Comtan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmacologically active catechol derivatives
Patent 5,446,194
Issued: August 29, 1995
Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
Assignee(s): Orion-yhtyma Oy
A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
Patent expiration dates:
- October 19, 2013
  ✓
  Drug substance

Oral compacted composition comprising catechol derivatives
Patent 6,599,530
Issued: July 29, 2003
Inventor(s): Kari; Vahervuo
Assignee(s): Orion Corporation
The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and croscarmellose sodium. The composition is premised on the discovery that croscarmellose sodium increases the release rate of entacapone or nitecapone from an oral compacted composition. Preferably the amount of croscarmellose sodium in the composition is at least 6% by weight, preferably from about 8% to about 16% by weight, especially from about 10% to about 14% by weight.
Patent expiration dates:
- September 14, 2018
  ✓
  Patent use: TREATMENT OF PARKINSON'S DISEASE
  ✓
  Drug product

Has a generic version of Stalevo 100 been approved?

No. There is currently no therapeutically equivalent version of Stalevo 100 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stalevo 100. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmacologically active catechol derivatives
Patent 5,446,194
Issued: August 29, 1995
Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
Assignee(s): Orion-yhtyma Oy
A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
Patent expiration dates:
- October 19, 2013
  ✓
  Drug substance

Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Patent 6,500,867
Issued: December 31, 2002
Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
Assignee(s): Orion Corporation
An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Patent expiration dates:
- June 29, 2020
  ✓
  Patent use: TREATMENT OF PARKINSON'S DISEASE
  ✓
  Drug product

Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
Patent 6,797,732
Issued: September 28, 2004
Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
Assignee(s): Orion Corporation
An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Patent expiration dates:
- June 29, 2020
  ✓
  Drug product

Has a generic version of ConZip been approved?

No. There is currently no therapeutically equivalent version of ConZip available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ConZip. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Extended release composition containing Tramadol
Patent 7,858,118
Issued: December 28, 2010
Inventor(s): Deboeck; Arthur M. & Vanderbist; Francis & Sereno; Antonio
Assignee(s): Galephar Pharmaceutical Research, Inc.
An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.
Patent expiration dates:
- April 11, 2022
  ✓
  Patent use: USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
  ✓
  Drug product

Has a generic version of Clobex been approved?

A generic version of Clobex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Clobex and have been approved by the FDA:

clobetasol propionate lotion; topical

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: December 4, 2008

Strength(s): 0.05% ^[AB]

clobetasol propionate shampoo; topical

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: June 7, 2011

Strength(s): 0.05% ^[AB]

clobetasol propionate spray; topical

Manufacturer: PADDOCK LLC

Approval date: June 16, 2011

Strength(s): 0.05% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clobex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
Patent 5,972,920
Issued: October 26, 1999
Inventor(s): Seidel; William E.
Assignee(s): Dermalogix Partners, Inc.
One or more formulations for treating psoriasis and other skin disorders characterized by redness, itching, flaking, scaling, and plaque-type growth. The formulation includes a carrier component, one or more active ingredient components, and a surfactant component. The carrier preferably includes an alcohol in substantially equal volume with isopropyl myristate. The active ingredient component preferably includes a superpotent or high-potency corticosteroid such as clobetasol propionate, an anti-flaking ingredient such as zinc pyrithione, or a combination of the two. It may also include an anti-fungal compound. The surfactant component preferably includes an alkyl sulfate such as sodium lauryl sulfate. The formulations made by applied topically either in spray form or as a direct-contact liquid.
Patent expiration dates:
- February 12, 2018
  ✓
  Drug product

Composition and method for treatment of psoriasis
Patent 5,990,100
Issued: November 23, 1999
Inventor(s): Rosenberg; E. William & Glenn; Thomas M. & Skinner, Jr.; Robert B. & Noah; Patricia W.
Assignee(s): Panda Pharmaceuticals, L.L.C.
The University of Tennessee Research Corporation
Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.
Patent expiration dates:
- March 24, 2018
  ✓
  Patent use: TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
  ✓
  Drug product

Topically applicable O/W emulsions having high glycol content and at least one biologically active agent
Patent 6,106,848
Issued: August 22, 2000
Inventor(s): Preuilh; Isabelle & Willcox; Nathalie
Assignee(s): Centre International de Recherches Dermatologiques
Stable, topically applicable oil-in-water bioaffecting emulsions having intermediate viscosity, characteristically ranging from 3 to 10 Pa.multidot.s, comprise (a) from 30% to 50% by weight of at least one pro-penetrating glycol, (b) at least one emulsifying agent, advantageously an anionic amphiphilic polymer, and (c) at least one biologically active agent, for example an active agent that modulates skin differentiation and/or proliferation and/or pigmentation, an anti-inflammatory, an antibacterial, an antifungal, etc.
Patent expiration dates:
- September 22, 2017

Foaming composition for washing and treating hair and/or scalp based on an active principle
Patent 7,316,810
Issued: January 8, 2008
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterized in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- June 17, 2019
  ✓
  Drug product

Foaming compositions for hair care
Patent 7,700,081
Issued: April 20, 2010
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- January 3, 2022
  ✓
  Patent use: TOPICAL TREATMENT OF SCALP PSORIASIS

Foaming composition for washing and treating hair and/or scalp based on an active principle
Patent 8,066,975
Issued: November 29, 2011
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterized in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- June 17, 2019
  ✓
  Drug product

Foaming compositions for hair care
Patent 8,066,976
Issued: November 29, 2011
Inventor(s): Preuilh; Isabelle & Guise; Anne-Emmanuelle & Willcox; Nathalie
Assignee(s): Galderma S.A.
The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.
Patent expiration dates:
- June 17, 2019
  ✓
  Drug product

Has a generic version of Reclast been approved?

No. There is currently no therapeutically equivalent version of Reclast available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reclast. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Substituted alkanediphosphonic acids and pharmaceutical use
Patent 4,939,130
Issued: July 3, 1990
Inventor(s): Jaeggi; Knut A. & Widler; Leo
Assignee(s): Ciba-Geigy Corporation
Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.
Patent expiration dates:
- September 2, 2012
  ✓
  Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  ✓
  Drug substance
  ✓
  Drug product
- March 2, 2013
  ✓
  Pediatric exclusivity

Pharmaceutical products comprising bisphosphonates
Patent 7,932,241
Issued: April 26, 2011
Inventor(s): Glausch; Alexandra & Löffler; Rolf & Sigg; Juergen
Assignee(s): Novartis AG
A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Patent expiration dates:
- February 5, 2028
  ✓
  Drug product
- August 5, 2028
  ✓
  Pediatric exclusivity

Method of administering bisphosphonates
Patent 8,052,987
Issued: November 8, 2011
Inventor(s): Horowitz; Zebulun D. & Richardson; Peter C. & Trechsel; Ulrich
Assignee(s): Novartis Pharmaceuticals Corporation
The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
Patent expiration dates:
- March 19, 2024
  ✓
  Patent use: TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

Related Exclusivities

Exclusivity expiration dates:
- August 17, 2010 - TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- October 16, 2010 - PEDIATRIC EXCLUSIVITY
- February 17, 2011 - PEDIATRIC EXCLUSIVITY
- December 19, 2011 - TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- March 15, 2012 - TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
- May 29, 2012 - PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Has a generic version of Clarinex-D 12 Hour been approved?

No. There is currently no therapeutically equivalent version of Clarinex-D 12 Hour available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clarinex-D 12 Hour. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

8-chloro-6,11-dihydro-11- ] (4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Patent 6,100,274
Issued: August 8, 2000
Inventor(s): Kou; Jim H.
Assignee(s): Schering Corporation
Stable pharmaceutical compositions containing 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cycloheptic[1,2-b ]pyridine("DCL") and a DCL protective amount of a pharmaceutically acceptable basic salt such as calcium dibasic phosphate and an amount of at least one disintegrant, preferably two disintegrates such as microcrystalline cellulose and starch sufficient to provide dissolution of at least about 80% by weight of the pharmaceutical composition in about 45 minutes and suitable for oral administration to treat allergic reactions in mammals such as man are disclosed.
Patent expiration dates:
- July 7, 2019
  ✓
  Drug product
- January 7, 2020
  ✓
  Pediatric exclusivity

Extended release oral dosage composition
Patent 6,709,676
Issued: March 23, 2004
Inventor(s): Wing-Kee Philip; Cho
Assignee(s): Schering Corporation
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Patent expiration dates:
- February 18, 2021
  ✓
  Patent use: ALLERGIC RHINITIS
  ✓
  Drug product

Compositions of descarboethoxyloratadine
Patent 7,214,683
Issued: May 8, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Drug product
- June 30, 2015
  ✓
  Pediatric exclusivity

Methods for the treatment of allergic rhinitis
Patent 7,214,684
Issued: May 8, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
- June 30, 2015
  ✓
  Pediatric exclusivity

Extended release oral dosage composition
Patent 7,618,649
Issued: November 17, 2009
Inventor(s): Cho; Wing-Kee Philip
Assignee(s): Schering Corporation
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Patent expiration dates:
- December 19, 2020
  ✓
  Patent use: A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
  ✓
  Drug product
- June 19, 2021
  ✓
  Pediatric exclusivity

Has a generic version of Skelid been approved?

No. There is currently no therapeutically equivalent version of Skelid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Skelid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Skelid.

Has a generic version of Carnitor been approved?

A generic version of Carnitor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Carnitor and have been approved by the FDA:

levocarnitine injectable; injection

Manufacturer: BEDFORD

Approval date: March 29, 2001

Strength(s): 200MG/ML ^[AP]

Manufacturer: LUITPOLD

Approval date: June 22, 2001

Strength(s): 200MG/ML ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: March 29, 2001

Strength(s): 200MG/ML ^[AP]

levocarnitine solution; oral

Manufacturer: HI TECH PHARMA

Approval date: October 25, 2007

Strength(s): 1GM/10ML ^[AA]

Manufacturer: LYNE

Approval date: August 10, 2004

Strength(s): 1GM/10ML ^[AA]

levocarnitine tablet; oral

Manufacturer: COREPHARMA

Approval date: September 20, 2004

Strength(s): 330MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carnitor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Treating chronic uremic patients undergoing periodical dialysis
Patent 6,335,369
Issued: January 1, 2002
Inventor(s): Claudio; Cavazza
Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Patent expiration dates:
- January 18, 2021
  ✓
  Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Treating chronic uremic patients undergoing periodical dialysis
Patent 6,429,230
Issued: August 6, 2002
Inventor(s): Claudio; Cavazza
Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
The method for the treatment chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Patent expiration dates:
- January 18, 2021
  ✓
  Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Treating chronic uremic patients undergoing periodic dialysis
Patent 6,696,493
Issued: February 24, 2004
Inventor(s): Claudio; Cavazza
Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Patent expiration dates:
- January 18, 2021
  ✓
  Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Has a generic version of Celebrex been approved?

No. There is currently no therapeutically equivalent version of Celebrex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Celebrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Substituted pyrazolyl benzenesulfonamides
Patent 5,466,823
Issued: November 14, 1995
Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
Assignee(s): G.D. Searle & Co.
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## or a pharmaceutically-acceptable salt thereof.
Patent expiration dates:
- November 30, 2013
  ✓
  Drug substance
- May 30, 2014
  ✓
  Pediatric exclusivity

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Patent 5,563,165
Issued: October 8, 1996
Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
Assignee(s): G. D. Searl & Co.
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1##
Patent expiration dates:
- November 30, 2013
  ✓
  Drug product
- May 30, 2014
  ✓
  Pediatric exclusivity

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Patent 5,760,068
Issued: June 2, 1998
Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S. & Docter; Stephen H. & Yu; Stella S.
Assignee(s): G.D. Searle & Co.
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: ##STR1## or a pharmaceutically-acceptable salt thereof.
Patent expiration dates:
- June 2, 2015
  ✓
  Patent use: TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
- December 2, 2015
  ✓
  Pediatric exclusivity

Has a generic version of Cetraxal been approved?

No. There is currently no therapeutically equivalent version of Cetraxal available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cetraxal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Cetraxal.

Related Exclusivities

Exclusivity expiration dates:
- May 1, 2012 - NEW DOSAGE FORM

Has a generic version of Stalevo 125 been approved?

No. There is currently no therapeutically equivalent version of Stalevo 125 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stalevo 125. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmacologically active catechol derivatives
Patent 5,446,194
Issued: August 29, 1995
Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
Assignee(s): Orion-yhtyma Oy
A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
Patent expiration dates:
- October 19, 2013
  ✓
  Drug substance

Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Patent 6,500,867
Issued: December 31, 2002
Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
Assignee(s): Orion Corporation
An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Patent expiration dates:
- June 29, 2020
  ✓
  Patent use: TREATMENT OF PARKINSON'S DISEASE
  ✓
  Drug product

Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
Patent 6,797,732
Issued: September 28, 2004
Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
Assignee(s): Orion Corporation
An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Patent expiration dates:
- June 29, 2020
  ✓
  Drug product

Has a generic version of Campral been approved?

No. There is currently no therapeutically equivalent version of Campral available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Campral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Campral.

Has a generic version of Strattera been approved?

A generic version of Strattera has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Strattera and have been approved by the FDA:

atomoxetine hydrochloride capsule; oral

Manufacturer: AUROBINDO PHARM

Approval date: September 13, 2010

Strength(s): 100MG ^[AB], 10MG ^[AB], 18MG ^[AB], 25MG ^[AB], 40MG ^[AB], 60MG ^[AB], 80MG ^[AB]

Manufacturer: MYLAN

Approval date: August 30, 2010

Strength(s): 100MG ^[AB], 10MG ^[AB], 18MG ^[AB], 25MG ^[AB], 40MG ^[AB], 60MG ^[AB], 80MG ^[AB]

Manufacturer: SANDOZ

Approval date: September 13, 2010

Strength(s): 100MG ^[AB], 10MG ^[AB], 18MG ^[AB], 25MG ^[AB], 40MG ^[AB], 60MG ^[AB], 80MG ^[AB]

Manufacturer: SUN PHARMA GLOBAL

Approval date: August 30, 2010

Strength(s): 100MG ^[AB], 10MG ^[AB], 18MG ^[AB], 25MG ^[AB], 40MG ^[AB], 60MG ^[AB], 80MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: October 1, 2010

Strength(s): 100MG ^[AB], 10MG ^[AB], 18MG ^[AB], 25MG ^[AB], 40MG ^[AB], 60MG ^[AB], 80MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: September 17, 2010

Strength(s): 100MG ^[AB], 18MG ^[AB], 25MG ^[AB], 40MG ^[AB], 60MG ^[AB], 80MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Strattera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Treatment of attention-deficit/hyperactivity disorder
Patent 5,658,590
Issued: August 19, 1997
Inventor(s): Heiligenstein; John H. & Tollefson; Gary D.
Assignee(s): Eli Lilly and Company
Tomoxetine, a norepinephrine uptake inhibitor, is used to treat attention-deficit/hyperactivity disorder.
Patent expiration dates:
- November 26, 2016
  ✓
  Patent use: TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- May 26, 2017
  ✓
  Patent use: TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- September 28, 2010 - USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- May 7, 2011 - MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- July 23, 2011 - CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY

Has a generic version of Celontin been approved?

No. There is currently no therapeutically equivalent version of Celontin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Celontin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Celontin.

Has a generic version of Ridaura been approved?

No. There is currently no therapeutically equivalent version of Ridaura available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ridaura. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ridaura.

Has a generic version of Sectral been approved?

Yes. The following products are equivalent to Sectral:

acebutolol hydrochloride capsule; oral

Manufacturer: AMNEAL PHARM

Approval date: December 30, 1999

Strength(s): EQ 200MG BASE ^[AB], EQ 400MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: April 24, 1995

Strength(s): EQ 200MG BASE ^[AB], EQ 400MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: October 18, 1995

Strength(s): EQ 200MG BASE ^[AB], EQ 400MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sectral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sectral.

Has a generic version of Revatio been approved?

No. There is currently no therapeutically equivalent version of Revatio available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Revatio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pyrazolopyrimidinone antianginal agents
Patent 5,250,534
Issued: October 5, 1993
Inventor(s): Bell; Andrew S. & Brown; David & Terrett; Nicholas K.
Assignee(s): Pfizer Inc.
Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
Patent expiration dates:
- March 27, 2012
  ✓
  Drug substance
  ✓
  Drug product
- September 27, 2012
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- May 7, 2012 - TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
- November 7, 2012 - PEDIATRIC EXCLUSIVITY
- November 20, 2012 - NEW DOSAGE FORM
- May 20, 2013 - PEDIATRIC EXCLUSIVITY

Has a generic version of Sensipar been approved?

No. There is currently no therapeutically equivalent version of Sensipar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensipar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Calcium receptor-active molecules
Patent 6,011,068
Issued: January 4, 2000
Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
Assignee(s): NPS Pharmaceuticals, Inc.
The Brigham and Women's Hospital
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Patent expiration dates:
- March 8, 2018
  ✓
  Drug substance
  ✓
  Drug product

Calcium receptor-active molecules
Patent 6,031,003
Issued: February 29, 2000
Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
Assignee(s): NPS Pharmaceuticals, Inc.
The Brigham and Women's Hospital
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Patent expiration dates:
- December 14, 2016
  ✓
  Patent use: METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- December 14, 2016

Calcium receptor-active compounds
Patent 6,211,244
Issued: April 3, 2001
Inventor(s): Van Wagenen; Bradford C. & Moe; Scott T. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
Assignee(s): NPS Pharmaceuticals, Inc.
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca.sup.2+ on a calcium receptor.
Patent expiration dates:
- October 23, 2015
  ✓
  Patent use: METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
  ✓
  Drug substance
  ✓
  Drug product

Calcium receptor-active molecules
Patent 6,313,146
Issued: November 6, 2001
Inventor(s): Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
Assignee(s): NPS Pharmaceuticals, Inc.
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Patent expiration dates:
- December 14, 2016
  ✓
  Drug substance
  ✓
  Drug product

Rapid dissolution formulation of a calcium receptor-active compound
Patent 7,829,595
Issued: November 9, 2010
Inventor(s): Lawrence; Glen Gary & Alvarez; Francisco J. & Lin; Hung-Ren H. & Ju; Tzuchi R.
Assignee(s): Amgen Inc.
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Patent expiration dates:
- September 22, 2026
  ✓
  Patent use: METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- March 8, 2011 - ORPHAN DRUG EXCLUSIVITY
- February 25, 2014 - TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- February 25, 2014 - INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- February 25, 2018 - ORPHAN DRUG EXCLUSIVITY

Thursday, September 22, 2016

Sensorcaine

Sensorcaine is a brand name of bupivacaine, approved by the FDA in the following formulation(s):

SENSORCAINE (bupivacaine hydrochloride - injectable; injection)

Manufacturer: APP PHARMS

Approved Prior to Jan 1, 1982

Strength(s): 0.25% ^[AP], 0.5% ^[AP], 0.75% ^[AP]

Has a generic version of Sensorcaine been approved?

Yes. The following products are equivalent to Sensorcaine:

bupivacaine hydrochloride injectable; injection

Manufacturer: HOSPIRA

Approved Prior to Jan 1, 1982

Strength(s): 0.25% ^[AP], 0.5% ^[AP], 0.75% ^[AP]

Manufacturer: HOSPIRA

Approval date: February 17, 1986

Strength(s): 0.5% ^[AP]

Manufacturer: HOSPIRA

Approval date: February 17, 1987

Strength(s): 0.25% ^[AP], 0.25% ^[AP]

Manufacturer: HOSPIRA

Approval date: March 3, 1987

Strength(s): 0.25% ^[AP], 0.5% ^[AP], 0.5% ^[AP], 0.75% ^[AP], 0.75% ^[AP]

Manufacturer: SAGENT STRIDES

Approval date: October 18, 2011

Strength(s): 0.25% ^[AP], 0.5% ^[AP]

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE (bupivacaine hydrochloride injectable; injection)

Manufacturer: INTL MEDICATED

Approval date: January 9, 2002

Strength(s): 0.25% ^[AP], 0.5% ^[AP], 0.75% ^[AP]

Manufacturer: SAGENT STRIDES

Approval date: October 18, 2011

Strength(s): 0.25% ^[AP], 0.5% ^[AP], 0.75% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensorcaine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sensorcaine.

Has a generic version of Rimso-50 been approved?

No. There is currently no therapeutically equivalent version of Rimso-50 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rimso-50. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Rimso-50.

Friday, September 23, 2016

SAMSCA (tolvaptan - tablet; oral)

Has a generic version of Samsca been approved?

Related Patents

Related Exclusivities

See also...

COMTAN (entacapone - tablet; oral)

Has a generic version of Comtan been approved?

Related Patents

See also...

STALEVO 100 (carbidopa; entacapone; levodopa - tablet; oral)

Has a generic version of Stalevo 100 been approved?

Related Patents

See also...

CONZIP (tramadol hydrochloride - capsule, extended release; oral)

Has a generic version of ConZip been approved?

Related Patents

See also...

CLOBEX (clobetasol propionate - lotion; topical)

CLOBEX (clobetasol propionate - shampoo; topical)

CLOBEX (clobetasol propionate - spray; topical)

Has a generic version of Clobex been approved?

clobetasol propionate lotion; topical

clobetasol propionate shampoo; topical

clobetasol propionate spray; topical

Related Patents

See also...

RECLAST (zoledronic acid - injectable; iv (infusion))

Has a generic version of Reclast been approved?

Related Patents

Related Exclusivities

See also...

CLARINEX-D 12 HOUR (desloratadine; pseudoephedrine sulfate - tablet, extended release; oral)

Has a generic version of Clarinex-D 12 Hour been approved?

Related Patents

See also...

SKELID (tiludronate disodium - tablet; oral)

Has a generic version of Skelid been approved?

Related Patents

See also...

CARNITOR (levocarnitine - injectable; injection)

CARNITOR (levocarnitine - solution; oral)

CARNITOR (levocarnitine - tablet; oral)

Has a generic version of Carnitor been approved?

levocarnitine injectable; injection

levocarnitine solution; oral

levocarnitine tablet; oral

Related Patents

See also...

CELEBREX (celecoxib - capsule; oral)

Has a generic version of Celebrex been approved?

Related Patents

See also...

CETRAXAL (ciprofloxacin hydrochloride - solution/drops; otic)

Has a generic version of Cetraxal been approved?

Related Patents

Related Exclusivities

See also...

STALEVO 125 (carbidopa; entacapone; levodopa - tablet; oral)

Has a generic version of Stalevo 125 been approved?

Related Patents

See also...

CAMPRAL (acamprosate calcium - tablet, delayed release; oral)

Has a generic version of Campral been approved?

Related Patents

See also...

STRATTERA (atomoxetine hydrochloride - capsule; oral)

Has a generic version of Strattera been approved?

atomoxetine hydrochloride capsule; oral

Related Patents

Related Exclusivities

See also...

CELONTIN (methsuximide - capsule; oral)

Has a generic version of Celontin been approved?

Related Patents

See also...

RIDAURA (auranofin - capsule; oral)

Has a generic version of Ridaura been approved?

Related Patents

See also...